Plex Pharmaceuticals is a scientifically-driven company with a vision to improve the lives of patients diagnosed with complex, degenerative diseases. Plex Pharmaceuticals is focused on the treatment of diseases generally caused by protein mis-folding such as ALS, Parkinson's Disease and cataracts.
Plex has a rich pipeline of drug discovery programs and a dedicated scientific team. To date, Plex Pharmaceuticals has been primarily funded through grants from the NIH and the MJFF. Plex’s drug discovery lab and operations are located in San Diego, California.
Company founded in 2009.
Acquired by Collidion, Inc. in 2017.
Plex (Latin for fold) pharmaceuticals (formerly CalAsia Pharmaceuticals) is an early stage biotechnology company which is focusing its drug discovery expertise on diseases caused by protein misfolding: ALS, Parkinson’s disease and cataracts. CalAsia Pharmaceuticals, the predecessor to Plex Pharmaceuticals, was founded in 2009 and raised almost $3,000,000 in non-dilutive funding from the NIH and the Michael J.Fox Foundation to support its efforts in fragment-based screening and structure-based drug design. Plex’s ALS effort is built around the work of Scientific Advisory Board member Dr. Arthur Horwich, Yale University School of Medicine. Dr. Horwich was one of the co-discoverers of the protein chaperone machinery, for which he received a Lasker Award. Plex pharmaceuticals additionally has a development program for Dengue, West Nile and Zika antiviral drugs which has also received support from the NIH and has worked on a novel brain-penetrant heat shock protein 90 (HSP90) inhibitor for glioblastoma.